Year in Review: New drug for psoriatic arthritis, biosimilars, and immune function is NOT a spectrum

Two leaders in the field of rheumatology discussed the most influential studies that have been done and issues that have come to the forefront this year: Apremilast, a new drug approved for psoriatic arthritis, the rise of biosimilar drugs, and a new way of thinking about immune dysfunction.